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Chloroquine diphosphate (CDP) is a helpful tool in the blood bank 
for two main applications. The most common application is to 
render direct antiglobulin test–positive red blood cells (RBCs) 
free from membrane-bound IgG; these treated RBCs can then be 
used for autologous adsorption and/or to determine the patient’s 
RBC phenotype. Another common use of CDP is to remove 
human leukocyte antigens (HLAs) from RBCs to help identify or 
exclude the presence of antibodies to HLAs expressed on RBCs, 
for example, Bennett-Goodspeed (Bg) antigens. In this review, 
the principles, applications, and limitations of using CDP are 
discussed. Immunohematology 2018;34:98–102.
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Antigen typing of red blood cells (RBCs) using an indirect 
antiglobulin test (IAT) method can be challenging when RBCs 
are coated with IgG antibodies and thus have a positive direct 
antiglobulin test (DAT). Commercially available monoclonal 
antisera that can be used at the direct agglutination phase 
without an IAT are not available for typing of all blood group 
antigens. For those monoclonal antisera that are available, 
false-positive and false-negative results can occur when 
testing untreated RBCs if they are strongly coated with IgG.1–3 
The majority of “in-house” or “rare” antiserum is collected 
from patients and is usually reactive only by the IAT. When 
there are no commercially available antisera that can be used 
by direct agglutination tests and/or the patient’s sample has 
a strongly positive DAT, there is a need for a reliable method 
to dissociate membrane-bound IgG to then obtain an accurate 
RBC phenotype using an IAT method.
Although chloroquine diphosphate (CDP) was reported 
in the 1970s to remove warm autoantibodies from DAT+ 
RBCs,4,5 its use was not applied to antigen-typing of RBCs with 
a positive DAT until the 1980s (by Edwards et al.6) There were 
only two other procedures available at that time—gentle heat 
elution (e.g., 45°C for 10–30 minutes or 56°C for 3 minutes)7 
or treatment with ZZAP, a combination of dithiothreitol (DTT) 
and papain.8 Heating RBCs above 37°C weakens antigens 
relative to the temperature and time of incubation9 and ZZAP 
destroys antigens sensitive to DTT and papain (Kell, Duffy, 




• 16–20% CDP solution at 
pH 5.0 ± 1
• Isotonic saline
• Pipettes
• Test tubes: 10 × 75 or 12 × 75 mm
• Calibrated centrifuge
RBCs = red blood cells; CDP = chloroquine diphosphate.
Procedural Steps — Room Temperature
• Mix 1 volume of washed, packed RBCs with 4 volumes of 16–20% 
CDP.
• Incubate mixture at room temperature.
• At 30-minute intervals, wash a small aliquot of RBCs at least three 
times, and perform DAT using anti-IgG to monitor the process of 
IgG dissociation. The mixture can be incubated for up to 2 hours.
• When the DAT is negative, wash the remaining CDP-treated RBCs 
at least three times with isotonic saline.
RBCs = red blood cells; CDP = chloroquine diphosphate;  





• 16–20% CDP solution at 
pH 5.0 ± 1
• Isotonic saline
• Pipettes
• Test tubes: 10 × 75 or 12 × 75 mm
• Calibrated centrifuge
• 37°C water bath or heat block
RBCs = red blood cells; CDP = chloroquine diphosphate.
Procedural Steps — 37°C
• Mix 1 volume of washed, packed RBCs with 4 volumes of 16–20% 
CDP.
• Incubate mixture at 37°C.
• At 5-minute intervals, wash a small aliquot of RBCs at least three 
times and perform a DAT using anti-IgG to monitor the process of 
IgG dissociation. The mixture can be incubated for up 30 minutes.
• When DAT is negative, wash the remaining CDP-treated RBCs at 
least three times with isotonic saline.
RBCs = red blood cells; CDP = chloroquine diphosphate;  
DAT = direct antiglobulin test.
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Use of CDP
MNS, etc.). Gentle heat elution and ZZAP are good methods 
for preparing RBCs for autoadsorption; CDP has also been 
described for this use.
Treatment of DAT+ RBCs with glycine-HCl/EDTA (also 
known as EDTA glycine acid [EDTA acid]) was described 
by Louie et al.10 and reviewed by Kosanke.11 It is quick and 
reliable but destroys Kell system antigens and Era. Microwave 
irradiation was also described to remove IgG from RBCs and 
allow phenotyping.12 All these methods have their limitations. 
Most significant is the potential for weakening or destroying 
RBC antigens when the treatment is done to prepare RBCs 
for phenotyping. Because of these limitations, there is a need 
to use more than one method in an immunohematology 
reference laboratory. Depending on the antigens of interest, an 
appropriate method can be selected to dissociate membrane-
bound IgG from DAT+ RBCs.
Bennett-Goodspeed (Bg) antigens are human leukocyte 
antigen (HLA) class I (HLA-A and HLA-B) weakly expressed 
on RBCs, including the reagent RBCs used in blood bank 
testing. Despite their clinical insignificance, Bg antibodies 
may interfere in routine antibody detection and identification 
tests by showing weak unexpected reactions without a distinct 
pattern. CDP and EDTA acid destroy Bg antigens on RBCs; 
thus, these reagents can be useful in identifying or excluding 
reactions caused by Bg antibodies.13,14
Principle
CDP diluted to 16–20 percent (wt/vol) at a final pH of 
5.0 ± 0.1 is used to dissociate membrane-bound IgG from 
RBCs.6,15 Issitt and Anstee16 suggested that the most likely 
mechanism for this dissociation involves neutralization of 
charged groups on amino acids that influence the shape 
of the antibody molecules that bind to antigens. Edwards 
et al.6 found that CDP was effective on 84 percent of in vivo 
sensitized DAT+ samples tested; results of other studies are 
summarized in Table 1. Factors that influence the ability of 
CDP to dissociate antibodies from DAT+ RBCs may be the IgG 
subclass of the antibody, the antibody affinity, the accessibility 
of the antigen-antibody complex, and the quantity of antibody 
bound to the RBCs.6 The temperature of CDP treatment (e.g., 
room temperature versus 37°C) and the sensitivity of the DAT 
method (e.g., tube versus gel) can also affect the outcome of 
CDP treatment.
CDP can remove HLAs expressed on RBCs (e.g., Bg 
antigens).13,14 This fact can be useful in antibody detection 
and identification tests where the antibodies may show weak 
reactivity with no apparent specificity. By testing a patient’s 
plasma with CDP-treated RBCs in parallel with untreated 
RBCs, the presence of Bg antibodies may be identified 
presumptively. The Bg antibodies may then be confirmed 
Table 1. Studies on the efficiency of CDP for clearing IgG versus other methods
Reference
IgG-coated RBC samples 
Results using RT or 37°C CDP method Results by other methodsNumber Type* Strength
6 56 In vivo 1–4+ RT = 47 (84%) neg NA
40 In vitro 3–4+ RT = 22 (55%) neg NA
10 30 In vivo Strong+ RT = 26 (87%) neg EDTA acid = 30 (100%) neg; 
ZZAP = 28 (93%) neg
12 15 In vivo 1–3+ RT = 4 (27%) neg Microwave = 7 (47%) neg
17 20 In vitro Variable RT = 10 (50%) neg
37°C = 20 (100%) neg





1–4+ RT = 26 (52%) neg by tube, 
22 (44%) neg by gel
EDTA acid = 48 (96%) neg by tube, 
42 (84%) neg by gel
56°C heat = 46 (92%) neg by tube, 
25 (50%) neg by gel
19 26 In vivo ±–4+ RT = 25 (96%) neg EDTA acid = 25 (96%) neg
20 93 In vivo w+–4+ RT = 29 (31%) â by gel EDTA acid = 59 (63%) â by gel
56°C heat = 36 (39%) â by gel
17 In vitro No data available RT = 5 (29%) neg by gel EDTA acid = 12 (71%) neg by gel
56°C heat = 9 (53%) neg by gel
*In vivo = direct antiglobulin test (DAT)+ red blood cells (RBCs); In vitro = RBCs coated with antibody in the laboratory.
CDP = chloroquine diphosphate; RT = room temperature; neg = negative; NA = not applicable; â = reduction in strength.
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or excluded by further testing with routine HLA laboratory 
methods or by testing with RBCs known to show strong 
expression of Bg antigens. Along with Bg, CDP may destroy 
or weaken other important RBC antigens (see Limitations). 
Because of the possible effect that CDP can have on these other 
antigens, caution must be taken in antibody exclusions when 
identifying interfering reactions due to Bg antibody using 
CDP-treated RBCs. Other blood group antigens reported to be 
affected by CDP are summarized in Table 2.
Procedural Steps
The supplies and procedural steps for CDP treatment 
are provided. If commercially manufactured CDP reagent is 
used, the manufacturer’s recommendations supersede what is 
described here.
The most common method involves CDP treatment at 
room temperature with an incubation time that varies from 
30 to 120 minutes.6,15 Briefly, 4 volumes of 16–20 percent 
chloroquine, pH 5.0 ± 0.1, are added to 1 volume of washed, 
packed DAT+ RBCs. After 30 minutes, a small subsample is 
removed and washed, and a DAT is performed using anti-
IgG. If the DAT is negative, then the rest of the sample can be 
washed and used for phenotyping and/or autoadsorption. If 
the DAT is still positive, then the incubation can continue for 
another 30 minutes and the process is repeated (to a maximum 
incubation time of 2 hours). An alternative method involves 
CDP treatment at 37°C.17,24,29 Beaumont et al.24 studied RBC 
T. Aye and P.A. Arndt
Table 2. Blood group antigens reported to be significantly affected or not affected by CDP
Blood group system/ 
antigen Significantly affected by CDP Not affected by CDP
ABH NDA (NI)6,13
Rh (D, C, e; reduced and saline antisera)21; (D; direct testing, few by 
IAT)22; (D, C, E, c, e, Cw; weakened at RT and 37°C)17
(NI)6,13,20; (C)23; (D, C, E, c, e at 37°C)24; (C, c, E, e)18
MNS (Mta)25 (NI)6,13,20; (S, s)18,19,26; (S)27; (Mg, Mta, He)13; (M, N, S, s at RT  
and 37°C)17
P1PK (P1 weakened at 37°C)17 (NI)6; (P1)13; (P1 at RT)17
Lewis (Lea, Leb, weakened at 37°C)17 (NI)6,13; (Lea, Leb at RT)17
Kell NDA (NI)6,13,20; (K, k)26; (K, k, Kpa, Kpb at RT and 37°C)17;  
(K, k at 37C)24; (K, k, Kpb)18; (K, Kpa)2
Duffy (Fyb)26; (Fyb, sig â after 2 hours)27; (NI, weakened)20 (NI)6,13; (Fya, Fyb)18,19,26; (Fya)2,27; (Fya, Fyb at RT and 37°C)17;  
(Fya, Fyb at 37°C)24
Kidd (Jkb weakened after 2 hours at RT, Jka weakened at 37°C)28;  
(Jkb at 37°C)24
(NI)6,13,20; (Jka, Jkb)18,19,26–28; (Jka, Jkb at RT and 37°C)17;  
(Jka at 37°C)24
Knops (NI)25 (Kna)27; (Kna, McCa, Yka)13; (Kna, McCa, Sla, Yka)23
Lutheran (Lub)26; (Lub, slight â)27 (Lub)26
JMH (JMH)26; (JMH, slight â)27 (JMH)13
Vel (Vel, sig â after 120 minutes)27 NDA
Yt (Yta)26; (Yta, sig â after 2 hours)27 (Yta)13,26





Diego NDA (Bpa, Rba, Wda, Wra, Vga)13
Indian NDA (Ina)13
Cost NDA (Csa)13,23
700 Series NDA (Bya)13
Miscellaneous NDA (Cad)13
CDP = chloroquine diphosphate; NDA = no data available; NI = specificities not indicated; IAT = indirect antiglobulin test; RT = room temperature; sig = 
significant; â = decrease. 
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treatment with CDP at 18°C, 25°C, 30°C, and 37°C. Incubation 
at 37°C is known to facilitate IgG elution; when incubating 
at 37°C, a subsample is removed and washed, and a DAT is 
performed using anti-IgG every 5 minutes (to a maximum 
incubation time of 30 minutes).24 In both methods of treatment 
(room temperature or 37°C), there is a threshold for incubation 
time where further incubation will not facilitate dissociation 
of antibody from RBCs, and the RBCs start to deteriorate. 
An alternative treatment method to dissociate IgG should be 
considered.
For removal of Bg antigens, Swanson and Sastamoinen13 
and Champagne et al.14 treated RBCs with commercially 
available chloroquine (Gamma-Quin; now available from 
Immucor, Norcross, GA) at room temperature for 90 minutes13 
or up to 2 hours.14 
Indications
CDP treatment can be used when a patient’s RBCs 
are coated with IgG and there is a need to perform antigen 
typing using antisera that are reactive only at the IAT phase 
and/or to prove the presence of an autoantibody by testing a 
patient’s plasma, serum, or eluate against DAT– autologous 
RBCs. Treatment with CDP dissociates membrane-bound 
IgG, allowing the treated RBCs to be tested at the IAT phase 
without interference. CDP treatment can also be used to 
avoid false-positive or false-negative results with monoclonal 
antisera when testing a patient’s RBCs that are strongly coated 
with IgG. For institutions that advocate the use of specific 
antigen–matched blood for transfusion in the presence of a 
warm autoantibody, an RBC phenotype from DAT+ RBCs 
can be obtained by treating the RBCs with a chemical such as 
CDP, as long as the patient has not been recently transfused. 
CDP treatment can also be used to remove or reduce RBC-
bound IgG so the patient’s RBCs can be used in autologous 
adsorptions (again, as long as the patient has not been recently 
transfused).
When Bg antibodies are suspected to cause weak 
interfering reactions in antibody detection or identification 
testing and a laboratory does not have the capability to identify 
HLA class I antibodies in a patient’s plasma, CDP-treated cells 
can be tested in parallel with untreated RBCs to presumptively 
exclude or identify Bg antibodies and to allow the identification 
of other RBC alloantibodies. The abrogation of reactivity with 
CDP-treated RBCs suggests that the weak interfering reactions 
may be caused by Bg antibodies.
Limitations
Weakening or denaturation of some RBC antigens was 
observed in some instances (Table 2). Per the manufacturer’s 
instructions for Gamma-Quin,15 CDP-treated RBCs can be 
typed with high-protein reagents or those reactive by IAT but 
should not be typed with saline-reactive or monoclonal blood 
typing reagents because of weaker-than-expected reactions. 
Mallory and Reid26 reported false-negative antigen typing of 
some CDP-treated RBCs when tested with some antiglobulin 
reacting antisera. McShane and Cornwall29 tested 90 
antibodies (specificities not given) and found that 63 showed 
reduced titration scores, and 25 were nonreactive when testing 
RBCs that had been treated with CDP for 30 minutes at 37°C. 
Most of these 25 antibodies were low titer or low avidity. They 
also treated RBCs with CDP at room temperature and saw 
a loss of reactivity, although less than that at 37°C.29 These 
investigators thus cautioned the use of rare single donor 
antibodies that are “low titer” or “low avidity” to obtain a 
phenotype on CDP-treated RBCs because of possible antigen 
weakening.29 Factors affecting the strength of antigens on 
CDP-treated RBCs include time and temperature of treatment; 
concentration, volume, and pH of CDP solution; and potency 
of antisera. Weaker results with treated RBCs will be more 
apparent if titration scores are used for comparison rather 
than results with undiluted antisera.
CDP does not always completely remove IgG from RBCs. 
Different publications show a wide variation (27–96%) in 
the effectiveness of CDP (Table 1). The variations may be 
due to differences in the antibody-coated RBCs and the CDP 
treatment methods used. RBCs with only partial removal of 
IgG may still be useful for antigen typing or autoadsorption 
purposes. Most studies comparing CDP with other methods 
found more effective IgG removal using EDTA acid (Table 1).
Another disadvantage of CDP, compared with EDTA 
acid, is that CDP treatment requires longer incubation time. 
At room temperature, CDP treatment requires a minimum 
incubation of 30 minutes (maximum, 2 hours) whereas EDTA 
acid treatment requires no more than a 2-minute incubation. 
In urgent situations where antigen typing must be performed 
on DAT+ RBCs—for example, to confirm the specificity of 
alloantibodies—it may be more practical to use EDTA acid than 
CDP. CDP, like EDTA acid, does not dissociate membrane-
bound complement, so it is important to use anti-IgG when 
testing CDP-treated or EDTA acid-treated RBCs. Note that, 
unlike CDP or EDTA acid, ZZAP can be used to remove RBC-
bound complement.30
Use of CDP
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When using commercially manufactured CDP for 
clinical testing, it is necessary to follow the manufacturer’s 
recommendations. Any steps taken outside the manufacturer’s 
recommendation should be validated in-house before 
implementing their use. If there is a concern about weakening 
of antigen by CDP treatment, an aliquot of RBCs known to carry 
a single dose expression of the antigen(s) under investigation 
should be treated and tested in parallel. The CDP-treated 
RBCs should be tested with a protein medium (e.g., 6–10% 
albumin) in parallel with the blood grouping reagents. If the 
results with the albumin control are positive, then the antigen 
typing results are invalid.
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